Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss, but data are lacking with respect to its effects on cardiovascular outcomes. METHODS In this international, double-blind, randomized, placebo-controlled trial, we randomly assigned, in a 1:1 ratio, 731 patients with heart failure, an ejection fraction of at least 50%, and a body-mass index (the weight in kilograms divided by the square of the height in meters) of at least 30 to receive tirzepatide (up to 15 mg subcutaneously once per week) or placebo for at least 52 weeks. The two primary end points were a composite of adjudicated death from cardiovascular causes or a worsening heart-failure event (assessed in a time-to-first-event analysis) and the change from baseline to 52 weeks in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating better quality of life). RESULTS A total of 364 patients were assigned to the tirzepatide group and 367 to the placebo group; the median duration of follow-up was 104 weeks. Adjudicated death from cardiovascular causes or a worsening heart-failure event occurred in 36 patients (9.9%) in the tirzepatide group and in 56 patients (15.3%) in the placebo group (hazard ratio, 0.62; 95% confidence interval [CI], 0.41 to 0.95; P…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the SUMMIT trial (for tirzepatide) showed a reduction in events regarding time to cardiovascular death or worsening heart failure over 104 weeks (HR 0•62, 0•41-0•95), 79”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [79]
In the citing paper
“Apart from improvements in multiple cardiometabolic risk factors, tirzepatide also improves various obesity-related complications such as obstructive sleep apnoea (OSA), metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction [28–30].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [30]
In the citing paper
“Both semaglutide and tirzepatide reduce the severity of heart failure with preserved ejection fraction (65, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [66]
In the citing paper
“Tirzepatide also lowers CRP levels in clinical trials in people with heart failure with preserved ejection fraction, or OSA (19, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [66]
In the citing paper
“In the SUMMIT trial (Study of Tirzepatide in Participants With Heart Failure With Preserved Ejection Fraction and Obesity), tirzepatide reduced the risk of the composite of cardiovascular death and worsening HF events.23”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [23]
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669
Self-citationSemaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2313917 · Cited by 758
Self-citationPacker, M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.509 · Cited by 656
Self-citationTirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541
The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF
Savji, N., Meijers, W. C., Bartz, T. M., Bhambhani, V., Cushman, M., Nayor, M., Kizer, J. R., Sarma, A., Blaha, M. J., Gansevoort, R. T., et al. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2018.05.018 · Cited by 499
Borlaug, B. A., Jensen, M. D., Kitzman, D. W., Lam, C. S. P., Obokata, M., & Rider, O. J. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac120 · Cited by 450
Self-citationPaulus, W. J., & Zile, M. R. (2021) · Circulation Research · doi:10.1161/circresaha.121.318159 · Cited by 393
Self-citationKosiborod, M. N., Deanfield, J., Pratley, R., Borlaug, B. A., Butler, J., Davies, M. J., Emerson, S. S., Kahn, S. E., Kitzman, D. W., Lingvay, I., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01643-x · Cited by 308
Self-citation
Cited by
Items 601–700 of 1,086
Xiao-yu, Z., Deng, C.-H., Zhong, J.-Y., Wu, Q., Chen, Q.-X., Gao, X.-Y., Xu, Y., Jiang, Z., Guo, M., & Teng, F. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104859 · Cited by 1
Nelson, R. A., Lai, Y.-C., Kil, S. H., Lee, H. S., Mortimer, J. E., & Wang, P. H. (2026) · The Oncologist · doi:10.1093/oncolo/oyag268 · Cited by 1
Medical treatments for obesity: what does the future have in store?
Bassatne, A., & Rizo, I. M. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag274 · Cited by 1
Porterfield, L. R., Nadeem, S., Swanson, D., Hayek, S. S., & Vaughan, E. M. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01448-6 · Cited by 2
Packer, M., Schiattarella, G. G., Petrie, M. C., Burkhoff, D., Butler, J., Lam, C. S. P., Zannad, F. M., Vaduganathan, M., & Borlaug, B. A. (2026) · Circulation · doi:10.1161/circulationaha.126.079235 · Cited by 3
Self-citationRoy, A.-S., Jolicoeur, M. E., Bérubé, L., Forcillo, J., Pacheco, C., Potter, B. J., Pelletier‐Galarneau, M., & Bouabdallaoui, N. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10661-z · Cited by 2
“Studies have demonstrated the benefits of GLP1RAs for HFpEF outcomes, including Tirz - epatide in SUMMIT [ 49] and Semaglutide in STEP-HFpEF [ 50].”
Yang, X., Cheng, K., Chen, C., Zhang, Y., & Wang, D. W. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177734 · Cited by 1
“Tirzepatide has shown efficacy in phase 2 MASH and clinical benefit in HFpEF with obesity, although these findings do not establish a direct mitochondrial or liver-to-heart mechanism [161,162].”
Incretin analogues as cardiovascular agents: a state-of-the-art review
Garaygordobil, D. A., Rico-Fontalvo, J. E., Hernández-Balbuena, B., Vinay, M., & Gonzalez-Arias, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1898812 · Cited by 1
“…the more recent expansion into heart failure with preserved ejection fraction (STEP-HFpEF, SUMMIT) and chronic kidney disease (FLOW), the cumulative evidence has transformed these molecules from incidentally cardioprotective antidiabetics into a cardiovascular therapy in their own right (5 – 15).”
Beyond glycemic control: clinical cardiovascular effects of tirzepatide—a narrative review
Alawad, A. O., Merghani, T. H., Fadelelmoula, T. E. Y., Elamin, N. A., Satti, S., Edris, A., Hakim, A., El-Hindi, R. F., Alhaj-Ali, A. A., Ibrahim, W. E., et al. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261469947 · Cited by 1
“85,110 Its ability to target multiple pathophysiological processes that include obesity, inflammation, insulin resistance, and endothelial dysfunction makes it a promising candidate for cardiovascular risk reduction.”
Mallardo, M., Messina, A., Monda, V., Marra, M. L., Monda, A., Allocca, S., Casillo, M., Maio, G. D., Perrone, P., Daniele, A., et al. (2026) · Nutrients · doi:10.3390/nu18172748 · Cited by 1
“Therefore, the assessment of anti-obesity therapy should not be limited to body weight, but should also consider whether patients are able to move more easily, perform daily activities with less difficulty, and experience better physical well-being [240].”
Ahad, A., Hullon, D., Akhavan, M., & Oskouyan, Z. (2026) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-026-10839-8 · Cited by 1
“…that activin receptor blockade can uncouple fat mass loss from lean mass loss during incretin-based weight reduction; the phase 2 trial of the anti-GDF15 antibody ponsegromab in cancer cachexia; and contempo - rary analyses of the age and sex dependence of circulating GDF15 and FGF21 [ 23–27].”
HFpEF-ABA Score for the Diagnosis and Prognosis of HFpEF in Outpatients With Type 2 Diabetes
Manzanares, R. G., Anguita, M., Muñiz, J., Barrios, V., Gimeno-Orna, J. A., Pérez, A., Rodríguez-Padial, L., & Gámez, M. A. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.103196 · Cited by 1
Patoulias, D., Karagiannidis, E., Maragkoudakis, S., Alexanian, I. P., Papadopoulos, C., & Fragakis, N. (2026) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2026.08.007 · Cited by 1
Non-positive Airway Pressure Therapies for Obstructive Sleep Apnoea and Central Sleep Apnoea
Mora, J., Sunwoo, B. Y., Ramsis, M., & Malhotra, A. (2026) · Cardiac failure review · doi:10.15420/cfr.2025.24 · Cited by 1
“58 Studies are ongoing regarding tirzepatide effects on hard cardiovascular outcomes.”
Effects of GLP-1 receptor agonists on body weight and cardiovascular outcomes: a review
van Maren, S., van Doorn, E. P. M., Smits, M. M., Tack, C. J., van Rossum, E. F. C., & Messaoudi, S. E. (2026) · Netherlands Heart Journal · doi:10.1007/s12471-026-02073-3 · Cited by 1
“Tirzepatide treatment reduced the risk on this composite endpoint (HR, 0.62; 95% CI, 0.41–0.95; P = 0.026) [40].”
InfluentialTseng, T., & Chang, R. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.09.010 · Cited by 1
Gastaldelli, A., Choi, E., Conde‐Knape, K., Göransson, O., Krook, A., Lehtonen, S. H., Roden, M., Schrauwen, P., Sparks, L. M., & Heni, M. (2026) · Diabetologia · doi:10.1007/s00125-026-06853-9 · Cited by 3
Davies, M. J., Aroda, V. R., Bajaj, M. S., ElSayed, N. A., Giorgino, F., Green, J., Kalyani, R. R., Maruthur, N. M., Mathieu, C., Rosas, S. E., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06855-7 · Cited by 1
Pulse pressure in heart failure—easy to assess, not so easy to understand
Weber, T., Haring, B., & Protogerou, A. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag319 · Cited by 1
Acute cardiovascular care 2024 in review: acute heart failure
Platz, E., Aleksić, M., & Verbrugge, F. H. (2024) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuae145 · Cited by 1
Recent Advancements in the Management of Heart Failure: A Review
Sanyaolu, S. E. (2025) · Premier Journal of Cardiology · doi:10.70389/pjc.100008 · Cited by 1
Review of the top 5 cardiology studies of 2023–24
Barry, A. R., Boswell, R., Babadagli, H. E., Chen, J. W., Cowley, E. C., Eberhardt, T. E., & May, T. A. (2025) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/17151635251339445 · Cited by 1
Carretero‐Gómez, J., Rodríguez, J. M. F., Doña, A. M., Miramontes‐González, J. P., Soler, J. J. G., Soto, M. I. P., Carrasco-Sánchez, F. J., Gómez-Delgado, F., Arévalo‐Lorido, J. C., & Martínez, P. P. (2025) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2025.502352 · Cited by 1
Algoritmo de diagnóstico y tratamiento del sobrepeso y obesidad 2025 de la redGDPS
Fernández, L. C., Pérez, J. S., Fernández, C. G., & Vela, N. S. (2025) · Diabetes práctica · doi:10.52102/diabet/pract.2025.2.art3 · Cited by 1
Ntelis, S., & Wojeck, B. S. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01349-0 · Cited by 1
“Tirzepatide has also been associated with improved health status in patients with obesity and HFpEF [23].”
Kudaiberdieva, G. (2024) · Heart Vessels and Transplantation · doi:10.24969/hvt.2024.529 · Cited by 1
Outpatient Diuretic Intensification Across the Cardiovascular-Kidney-Metabolic Spectrum
Marques, P. S., & Ferreira, J. P. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3611 · Cited by 1
“Consequently, outpatient diuretic intensification has been gradually included as an endpoint in HF clinical trials, leading to an increased number of events and thereby reducing the size, duration, and associated costs of outcome-driven RCTs. 7 However, little is known about its prognostic significance in other CKM po…”
InfluentialMcCartney, F. (2025) · Therapeutic Delivery · doi:10.1080/20415990.2025.2469483 · Cited by 1
Treatment of obesity-related HFpEF: a STEP closer to the SUMMIT
Karakasis, P., Fragakis, N., Ruža, I., Stachteas, P., & Patoulias, D. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2477429 · Cited by 2
Holistic View of Tirzepatide’s Role in Obesity-Related HFpEF
Pagidipati, N. J. (2025) · Circulation · doi:10.1161/circulationaha.125.073439 · Cited by 1
Kumar, A., Scroggie, S., Sarkar, T. D., Hepokoski, M., & Malhotra, A. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2561067 · Cited by 1
“Additionally, in the SUMMIT trial, tirzepatide led to a lower risk of death from cardiovascular causes or worsening heart failure in patients with heart failure with preserved ejection fraction (HFpEF) [11].”
Adiposity at the Core of Cardiometabolic Disease
Spatz, E. S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.056 · Cited by 1
Bridging Gaps in Heart Failure Science: Toward a More Integrated Future
Liu, J., & Cheng, T. (2025) · Life · doi:10.3390/life15101613 · Cited by 1
“Similarly, findings from the SUMMIT trial underscored tirzepatide’s potential to alleviate circulatory overload and mitigate end-organ damage in obese individuals [8,9].”
Vest, A. R., & Deswal, A. M. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102715 · Cited by 1
Incretin therapy for cardiovascular disease: opportunities, mechanistic gaps, and challenges
Raaschou-Pedersen, D. E. T., & Sattar, N. A. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf983 · Cited by 1
GLP-1RA Use and the Risk of Heart Failure in Patients With Diabetes: Association or Causation?
Inoue, K., & Kazi, D. S. (2026) · Circulation · doi:10.1161/circulationaha.126.078150 · Cited by 1
Murugadoss, K., Venkatakrishnan, A. J., & Soundararajan, V. (2026) · Preprints.org · doi:10.64898/2026.04.23.26351609 · Cited by 1
Ciudin, A., Baker, J. L., Belančić, A., Busetto, L., Diker, D., Fábryová, Ľ., Frühbeck, G., Goossens, G. H., Gordon, J., Monami, M., et al. (2026) · medRxiv · doi:10.64898/2026.04.19.26351196 · Cited by 1
New Insights Into Delaying Renal Progression: Cardiovascular, Renal & Metabolic Medicine
Daoud, R. M., Spencer, S., Desborough, R., & Bhandari, S. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm53144 · Cited by 1
El‐Sheikh, M., Sillassen, C. D. B., Wisborg, F. D., Hove, J. D., Dirksen, C., Lee, M. M. Y., Jakobsen, J. C., & Grand, J. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-103668 · Cited by 2
Riccardi, M., Ostrominski, J. W., Chatur, S., Lombardi, C., Volterrani, M., Metra, M., Savarese, G., Vaduganathan, M., Solomon, S. D., & Inciardi, R. M. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag074 · Cited by 1
Trenas, A., Prieto-Laín, N., Velasco, M. Á. P., Padilla-Leiva, C., Pérez-Ruiz, J. M., Ruíz-Rodríguez, F. I., Gómez‐Huelgas, R., Bernal-López, M. R., & Perez-Belmonte, L. M. (2026) · Pharmaceuticals · doi:10.3390/ph19060894 · Cited by 1
“Similar observations have recently been reported with tirzepatide, a dual GIP/GLP-1ra, which was associated with improvements in HF outcomes and health status in patients with HFpEF and obesity [15].”
He, J., Wei, J., Wang, B., Ru-fei, L., Wang, W., & Li, Y. (2026) · Biomolecules · doi:10.3390/biom16070989 · Cited by 1
“Semaglutide has been approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity, and tirzepatide has shown beneficial effects in patients with obesity-related heart failure with preserved ejection fraction [11,12].”
Effects of Tirzepatide in Obesity-Related HFpEF by Sex
Borlaug, B. A., Zile, M. R., Kramer, C. M., Litwin, S. E., Ye, W., Ou, Y., Hurt, K. C., Murakami, M., & Packer, M. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103218 · Cited by 2
Self-citationHeart failure with preserved ejection fraction: current insights and emerging therapeutic directions
Kim, J., Eom, G. H., & Yoon, S. (2025) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.25.250 · Cited by 2
Suastika, L. O. S., Bando, Y., Hoshino, K., Koitabashi, N., Saito, Y., Yuasa, S., & Nakamura, K. (2026) · Nutrients · doi:10.3390/nu18111688 · Cited by 1
“Tirzepatide, a dual GIP/GLP-1RA, has shown substantial weight reduction and improvement in health status in patients with HFpEF with obesity, suggesting that incretin-based pharmacotherapy may continue to evolve as a cornerstone in cardiometabolic HF management [16].”
InfluentialZhang, X., Zhang, H., Fu, J., Feng, S., & Wang, Y. (2026) · International Journal of General Medicine · doi:10.2147/ijgm.s626604 · Cited by 1
“48 However, no trial has tested whether CHIP carriers, or specific CHIP genotypes such as TET2 -CHIP, derive differential benefit from SGLT2 inhibitors, GLP-1 receptor agonism, or dual GIP/GLP-1 receptor agonism.”
Windy City Breakthroughs: Highlights from the American Heart Association Scientific Sessions 2024
HAJDUCZOK, A. G., Stives, D., Fabbri, M., DONALD, E. M., Maning, J., & Mentz, R. J. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.11.006
IDRIS, I. R. (2024) · Diabetes Obesity and Metabolism Now · doi:10.1002/doi2.70008
Urbańska, K., Popiela, D., Stojak, Ł., Kwiatkowski, F., Grego, K., Grego, M., Baczewski, M., & Czyż, W. (2025) · Quality in Sport · doi:10.12775/qs.2025.37.57002
Thérapeutiques de l’obésité et maladies cardiovasculaires
Lassen, P. B., & Aron‐Wisnewsky, J. (2025) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2024.12.006
Maning, J., Lala, A., & Mentz, R. J. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.12.003
Liuzzo, G., & Patrono, C. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf013
Balancing Fat Loss and Muscle Loss in the Quest to Reduce Obesity in Patients with Heart Failure
Litwin, S. E. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.01.004
Self-citationSUMMIT: Tirzepatide reduces cardiovascular events in HFpEF plus obesity
van den Heuvel, R. (2025) · doi:10.55788/d9fd7622
Resilience selection: a grave potential bias in clinical trials
Watve, M., Shunyaka, P., & Keskar, A. (2026) · International Journal of Clinical Trials · doi:10.18203/2349-3259.ijct20261391
Medical management of obesity: unlocking the potential
Xiang, A. S., & Sumithran, P. (2025) · Climacteric · doi:10.1080/13697137.2025.2455177 · Cited by 1
“…study of tirzepatide for HFpeF reported an improvement in heart failure symptoms as well as a 38% reduction in a composite of heart failure urgent visit or hospitalization, oral diuretic intensification or cardiovascular death when compared to placebo over a median follow-up of 104 weeks [30].”
Inkretin-(Co-)Agonisten: Wo geht die Reise hin?
Sonnet, M. (2025) · Info Diabetologie · doi:10.1007/s15034-024-5066-z
What Counts for Worsening Heart Failure Events
Fonarow, G. C., Hernandez, A. F., Udelson, J. E., & Yancy, C. W. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.0042
Update in Outpatient General Internal Medicine: Practice-Changing Evidence Published in 2024
Wingo, M. T., Andersen, C. A., Bhuiyan, M. N., Sytsma, T. T., Huber, J. M., & Wieland, M. L. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.02.016
Atrial Fibrillation and Heart Failure
Kusumoto, F. M. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.01.004
Shi, F., Agrawal, V., Munkhjargal, U., Kobeck, E., Patel, H. U., Zhang, W., & Collins, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.02.640935
“Drugs originally developed for diabetes and obesity, such as sodium-glucose transport protein 2 inhibitors and incretin-based weight loss medications, have shown clinically significant benefits in HFpEF 30-32 , suggesting targeting such comorbidities is a valid therapy for HFpEF.”
Anti-Obesity Agents on the Horizon
Kim, S. H. (2025) · Korean Journal of Family Practice · doi:10.21215/kjfp.2025.15.1.2
Samajdar, S. S., & Joshi, S. (2025) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-025-01475-0
“The SUMMIT Trial provided robust evidence supporting the use of Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, for improving clinical outcomes in this population [1].”
Leading the Charge in Obesity Management: A Call to Action for Cardiovascular Nursing
Bryant, E., Laing, K., Langdon, K. D., Salisbury, H., & Villavaso, C. D. (2025) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0000000000001192
Obesity and heart failure—the role of GLP-1 receptor agonists
Simonis, G., & Schatz, U. (2025) · Herz · doi:10.1007/s00059-025-05312-2
“Veryrecently, theresultsoftheSUMMIT trial [37] were published.”
Therapieprinzipien bei Adipositas – was ändert sich in der aktualisierten S3-Leitlinie?
Rohmann, N., Hollstein, T., & Laudes, M. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01900-w · Cited by 1
Pedicino, D., & Liuzzo, G. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf236
Reimagining Heart Failure Care: Highlights from ACC 2025
HAJDUCZOK, A. G., DONALD, E. M., Hussien, M., Fabbri, M., Stives, D., CAMPBELL, P., & DeFilippis, E. M. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.04.005
Nesti, L., Santoni, L., Sacchetta, L., Chiriacò, M., Cimbalo, N., Gallo, S., Nesti, G., Pugliese, N. R., Tricò, D., & Natali, A. (2025) · il Diabete · doi:10.30682/ildia2501e · Cited by 1
The Role of GLP-1R and GIPR Agonism in Heart Failure
Sedrak, P., & Connelly, K. A. (2025) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2025.3138 · Cited by 1
Iwakura, K., Okamura, A., Iwanaga, Y., Koyama, Y., Tanaka, N., Okada, M., Seo, M., Yamada, T., Yano, M., Hayashi, T., et al. (2025) · medRxiv · doi:10.1101/2025.05.13.25327566
Recent advances in the pharmacological treatment of obesity
Nam, G. E. (2025) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0058 · Cited by 1
High-Complexity Questions and Their Answers for Everyday Heart Failure
de Santamaría, A. C. S., Pérez-Santana, J., Croset, F., Esterellas-Sánchez, L. K., Lobo-Antuña, V., Martínez, M. R., Botero, S. N. R., Sacristán, H. G., Pérez-Silvestre, J., Rodríguez, J. M. F., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113993
“An example of this is the SUMMIT-HF study [7] with Tirzepatide, where patients with an apparently correct diagnosis of HFpEF had NT-proBNP levels of 196 pg/mL and 169 pg/mL in the Tirzepatide and placebo groups, respectively.”
Time to Rethink our Approach to Guidelines? International Cascade Guidelines for Heart Failure
Atherton, J. J., Sindone, A. P., & Coats, A. J. S. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.05.093
Addressing Comorbidities in Heart Failure
Tobin, R. E., Rantanen, P., Lyle, M. A., & Sennhauser, S. (2025) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.04.011
Gewichtsreduktion mit Inkretinmimetika – Chancen und Risiken
Zech, T., Kirchweger, B., & Fürst, R. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01918-0
Protocolo terapéutico de la insuficiencia cardíaca con fracción de eyección conservada
Morán, J. S., Romo, E. G., Barros, A. L., González, C. T., Ruiz-Saavedra, A., & Lledó, A. G. (2025) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2025.06.015
Insuficiencia cardíaca crónica con fracción de eyección del ventrículo izquierdo conservada
Morán, J. S., Romo, E. G., Barros, A. L., Ruiz-Saavedra, A., González, C. T., & Lledó, A. G. (2025) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2025.06.012
Tirzepatide in Obesity-Related Heart Failure With Preserved EF
Fauchier, L., Lochon, L., & Lenormand, T. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.549
Kramer, C. M., Borlaug, B. A., Zile, M. R., & Packer, M. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.04.034
Self-citationAbbate, A. (2025) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001733
Pivotal Trials in Heart Failure in 2024—Putting Evidence into Clinical Practice!
Thandi, P., Pradhan, A. K., & Behera, S. K. (2025) · International Journal of Angiology · doi:10.1055/a-2624-5735
Übergewicht und Frauengesundheit: Gynäkologische Erkrankungen im Zusammenhang mit Adipositas
Franz, M. (2025) · gynäkologie + geburtshilfe · doi:10.1007/s15013-025-6117-9
“In verschiedenen Studien konnten verschiedene positive Wirkungen von Semaglutid und Tirzepatid gezeigt werden [14, 15, 16]: — Verbesserung/Entfettung der Leber bei nicht alkoholischer Fettleber In einer Studie, die vor Kurzem in „Nature Medicine“ publiziert wurde, analysierten Forschende anhand der…”
Identifying High-Risk Obese Individuals Without Diabetes for GLP-1RA Therapy Using Coronary CTA
Blair, C. V., Huck, D. M., Besser, S. A., Cardoso, R. N., Shiyovich, A., Berman, A. N., Biery, D. W., Weber, B., Petranović, M., Nasir, K., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101995
Body Mass Index, Central Adiposity, and HFpEF
Klein, K. R., Almandoz, J. P., McGuire, D. K., & Lingvay, I. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.05.043
The Role of Medical Therapy in Hypertrophic Cardiomyopathy
Lee, J.-W., Chun, K., Choi, E., & Seo, J. (2025) · Heart Failure Clinics · doi:10.1016/j.hfc.2025.06.005
Clinical perspective on non-sleepy obstructive sleep apnea; to treat or not to treat?
Luu, S., Nanayakkara, B., & Yee, B. J. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2539542
“…liraglutide and tirzepatide have demonstrated cardiometabolic benefits, including resolution of metabolic dysfunction-associated steatohepatitis [127,128], reduced risk of cardiovascular death or worsening heart failure [129,130], and prevention of progression to type 2 diabetes mellitus [131,132].”
Incretin integration: Charting the future of cardiovascular-kidney-metabolic health
Wang, C. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001277
Beyond the Skinfolds: Diagnostic and Therapeutic Hope for the Obese and Formerly Obese
Miller, D. D. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.07.014
Adipositas und Herz: neue Medikamente und neue Strategien für Kardiologen
Hollstein, T. (2025) · Aktuelle Kardiologie · doi:10.1055/a-2606-7020
“Eine umfassende Aufklärung und Gegenstrategien etwa kleinere Mahlzeiten, langsame Aufdosierung oder spezielle Ernährungs-empfehlungen”
Visceral adiposity, aortic stiffness, and cardiovascular risk
Harada, T., & Borlaug, B. A. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf516
Self-citationHacking, D. F., Baqar, S., Vaughan, R., & Craven, A. (2025) · Anaesthesia and Intensive Care · doi:10.1177/0310057x251355289
“19 However, it was soon noted that their efficacy extended well beyond weight loss into the treatment of HFpEF 20–22 and MASH.”
Safety analysis of tirzepatide in clinical practice
Shnaider, K. O., Kondrakhin, A. P., Maksimov, М. L., Balashova, E. P., Beschetnov, I. D., Akhmadieva, A. A., & Martynova, S. A. (2025) · Glavvrač (Chief Medical Officer) · doi:10.33920/med-03-2508-03
Can tirzepatide transform HFpEF management in Pakistan? a call for action
Soomro, A. M. (2025) · Journal of the Pakistan Medical Association · doi:10.47391/jpma.30399
Fauchier, L., Lochon, L., Lenormand, T., Pierre, B., Bodin, A., Guglieri, M., & Bisson, A. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70012
Obesity and Heart Failure: The (Fried) Chicken or the Egg?
Foster, L., Byrne, K. P. A., & Rivett, G. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.08.046
Emerging Therapeutic Agents for Obesity and Future Perspectives
Otoda, T. (2025) · Journal of Nihon University Medical Association · doi:10.4264/numa.84.4_185
Incretin-Based Therapies and Heart Failure Outcomes
Savarese, G., & Butler, J. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.022
Metadata
- Authors
- Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., Hurt, K. C., Murakami, M., & Borlaug, B. A.
- Affiliations
- Cleveland Clinic (US)
- From Baylor University Medical Center, Dallas (M.P.); Imperial College, London (M.P.); RHJ Department of Veterans Affairs, Health System and Medical University of South Carolina, Charleston (M.R.Z., S.E.L.); the Cardiovascular Division, Department of Medicine, University of Virginia Health System, Charlottesville (C.M.K.); Flourish Research, Boca Raton, FL (S.J.B.); the Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland (V.M.); the Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China (J.G.); Eli Lilly, Indianapolis (G.J.W., Y.O., M.C.B., K.C.H., M.M.); and the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-01-30
- Volume
- 392
- Issue
- 5
- Pages
- 427-437
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4404437149
- Semantic Scholar
- aeedfcfb5543cef26bd4f4576e1c5a59b4d2424f
- Cited by
- 1,009
- References
- 30
- Citations by year
- 2026: 496 · 2025: 494
- FWCI
- 303.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company (N/A)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- tirzepatide, heart failure with preserved ejection fraction, obesity, GIP/GLP-1 receptor agonist, weight loss, cardiovascular mortality, worsening heart failure, Kansas City Cardiomyopathy Questionnaire, quality of life, body mass index, GLP-1 receptor agonists, GIP receptor agonist, cardiovascular outcomes, weight loss treatment, heart failure with reduced ejection fraction
- MeSH terms
- Tirzepatide, Aged, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Humans, Male, Middle Aged, Obesity, Quality of Life, Stroke Volume, Weight Loss, Body Mass Index, Treatment Outcome, Glucagon-Like Peptide 1, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.